Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 281

Sort by

Sort Order Select

Journal Articles

FcRn augments induction of tissue factor activity by IgG-containing immune complexes

Douglas B. Cines, Sergei Zaitsev, Lubica Rauova, Ann H. Rux, Victoria Stepanova, Sriram Krishnaswamy, Amrita Sarkar, M. Anna Kowalska, Guohua Zhao, Alan E. Mast, Laurence J. Blumberg, Keith R. McCrae, Mortimer Poncz, Jonathan J. Hubbard, Michal Pyzik, Richard S. Blumberg

Blood (2020) 135 (23): 2085–2093.

https://doi.org/10.1182/blood.2019001133

Published: 2020

Includes: Supplemental data

Journal Articles

Pluripotent stem cell–derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity

Huang Zhu, Robert H. Blum, Ryan Bjordahl, Svetlana Gaidarova, Paul Rogers, Tom Tong Lee, Ramzey Abujarour, Gregory B. Bonello, Jianming Wu, Pei-Fang Tsai, Jeffrey S. Miller, Bruce Walcheck, Bahram Valamehr, Dan S. Kaufman

Blood (2020) 135 (6): 399–410.

https://doi.org/10.1182/blood.2019000621

Published: 2020

Includes: Multimedia, Supplemental data

Journal Articles

Ibrutinib Therapy Downregulates Toso, the Fcr for IgM, Expression in CLL Patients

Mariela Sivina, Gordon Duncan, MSc, Takashi Sakamoto, MD PhD, Ekaterina Kim, MS, Alicia Vaca, PhD, Elena Maria Hartmann, MD, Michael J Keating, MBBS, Alessandra Ferrajoli, MD, William G. Wierda, MD PhD, Tak Mak, PhD DSc, Andreas Rosenwald, MD, Jan A. Burger, MD PhD

Blood (2019) 134 (Supplement_1): 5448.

https://doi.org/10.1182/blood-2019-125716

Published: 2019

Journal Articles

T-Cell Mediated Cytopenias in Patients with Myelodysplastic Syndromes Respond to Intravenous Immunoglobulin

Jonathan Feld, MD, Francesca Schieppati, MD, Rosalie Odchimar-Reissig, RN, Erin P. Demakos, RN, Shyamala C. Navada, MD, Lewis R. Silverman, MD

Blood (2019) 134 (Supplement_1): 4260.

https://doi.org/10.1182/blood-2019-128656

Published: 2019

Journal Articles

Phase I/II, Open-Label, Adaptive Study of Oral Bruton Tyrosine Kinase Inhibitor PRN1008 in Patients with Relapsed/Refractory Primary or Secondary Immune Thrombocytopenia

David J. Kuter, Ralph V. Boccia, MD, Eun-Ju Lee, MD, Merlin Efraim, MD, Nikolay Tzvetkov, MD, Jiri Mayer, MD, Marek Trněný, MD, Milan Kostal, MD, Roman Hajek, MD, Vickie McDonald, MD, Olga Bandman, MD, Regan Burns, Ann Neale, Dolca Thomas, MD, Nichola Cooper, MD MRCP

Blood (2019) 134 (Supplement_1): 87.

https://doi.org/10.1182/blood-2019-122336

Published: 2019

Journal Articles

Impacts of a Proliferation-Inducing Ligand on Current Therapeutic Monoclonal Antibody-Induced Cytotoxicity Against Human Multiple Myeloma Cells

Liang Lin, PhD, Shih-Feng Cho, MD PhD, Kenneth Wen, Tengteng Yu, MD PhD, Phillip A Hsieh, Yuyin Li, PhD, Gang An, MD, Lugui Qiu, MD PhD, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD, Yu-Tzu Tai, PhD

Blood (2019) 134 (Supplement_1): 3105.

https://doi.org/10.1182/blood-2019-130927

Published: 2019

Journal Articles

Understanding How Fc-Modification Transforms a Pathogenic Heparin-Induced Thrombocytopenia (HIT)-like Monoclonal Antibody into a Novel Treatment for Sepsis

Kandace Gollomp, MD, Amrita Sarkar, PhD, Gowthami Arepally, MD, Douglas B. Cines, MD, M. Anna Kowalska, PhD, Lubica Rauova, MD PhD, Mortimer Poncz, MD

Blood (2019) 134 (Supplement_1): 10.

https://doi.org/10.1182/blood-2019-123132

Published: 2019

Journal Articles

Phase 2 Study of Efgartigimod, a Novel FcRn Antagonist, in Adult Patients with Primary Immune Thrombocytopenia

Adrian C. Newland, Blanca Sánchez-González, László Rejtő, Miklos Egyed, Nataliya Romanyuk, Marie Godar, Katrien Verschueren, Domenica Gandini, Peter Ulrichts, Jon Beauchamp, Torsten Dreier, E. Sally Ward, Marc Michel, Howard A. Liebman, Hans De Haard, Nicolas Leupin, David J. Kuter

Blood (2019) 134 (Supplement_1): 895.

https://doi.org/10.1182/blood-2019-128022

Published: 2019

Journal Articles

Rozanolixizumab, an Anti-FcRn Antibody: Final Results from a Phase II, Multiple-Dose Study in Patients with Primary Immune Thrombocytopenia

Tadeusz Robak, MD, Maciej Kaźmierczak, Isidro Jarque, Vasile Musteata, MD PhD, Jacek Trelinski, Nichola Cooper, MD MRCP, Peter Kiessling, Ute Massow, Franz Woltering, Rose Snipes, Juan Ke, Grant Langdon, Birgit Haier, James B. Bussel, MD, Stephen Jolles

Blood (2019) 134 (Supplement_1): 897.

https://doi.org/10.1182/blood-2019-129839

Published: 2019

Journal Articles

Pathogenic Antibodies in Heparin-Induced Thrombocytopenia Specifically Target an Immunodominant Region on Platelet Factor 4

Angela Huynh, PhD, Donald M. Arnold, MD, John G. Kelton, MD, Rumi Clare, BSc, Marina Ivanova, Ishac Nazy, PhD

Blood (2019) 134 (Supplement_1): 219.

https://doi.org/10.1182/blood-2019-131462

Published: 2019

Journal Articles

Preclinical Characterization of an ANTI-CD38/CD3 T CELL-Redirecting Bispecific Antibody

Xiao He, PhD, Yanliang Zhang, PhD, Yun Wei Lai, MSc, Stephanie Baguley, MSc, Yan Li, PhD, Xia Cao, MSc, Ying Yan, PhD, Ken Takeshita, MD, Jerome B. Zeldis, MD PhD, Henry Ji, PhD, Gunnar F. Kaufmann, PhD

Blood (2019) 134 (Supplement_1): 4463.

https://doi.org/10.1182/blood-2019-131540

Published: 2019

Journal Articles

Immune-Tumor Interactions in Resistance to Cancer Immunotherapy

Kai W. Wucherpfennig, MD PhD

Blood (2019) 134 (Supplement_1): SCI-45.

https://doi.org/10.1182/blood-2019-121065

Published: 2019

Journal Articles

Engineering High Affinity and Cleavage Resistant CD16 to Augment ADCC of Placental Hematopoietic Stem Cells-Derived Natural Killer Cells

Xuan Guo, PhD, Srinivas Somanchi, PhD, Rohit Mathur, PhD, Shuyang He, PhD, Qian Ye, PhD, Andrea Difiglia, BS, Salvatore Rotondo, MS, Hemlata Rana, MS, Weifang Ling, PhD, James Edinger, PhD, Robert Hariri, MD PhD, Xiaokui Zhang, PhD

Blood (2019) 134 (Supplement_1): 1576.

https://doi.org/10.1182/blood-2019-127009

Published: 2019

Journal Articles

Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia

Valentina Griggio, Candida Vitale, MD, Maria Todaro, PhD, Francesca Romana Mauro, Chiara Salvetti, MD, Daniela Pietrasanta, Iolanda Donatella Vincelli, MD, Lydia Scarfo, MD, Giovanni Del Poeta, MD, Gianluca Gaidano, MD PhD, Valter Gattei, MD, Robin Foà, MD, Mario Boccadoro, MD, Marta Coscia, MD

Blood (2018) 132 (Supplement 1): 4412.

https://doi.org/10.1182/blood-2018-99-116068

Published: 2018

Journal Articles

Pre-Clinical Efficacy of CD123-Targeting Antibody-Drug Conjugate IMGN632 in Blastic Plasmacytoid Dentritic Cell Neoplasm (BPDCN) Models

Qi Zhang, PhD, Tianyu Cai, PhD, Lina Han, PhD, Vinitha Mary Kuruvilla, Sharlene Adams, PhD, Sloss M Callum, Karine Harutyunyan, PhD, Andrew A. Lane, MD PhD, Yelena Kovtun, PhD, Naval G. Daver, MD, Naveen Pemmaraju, MD, Patrick Zweider McKay, MD PhD, Marina Y. Konopleva, MD PhD

Blood (2018) 132 (Supplement 1): 3956.

https://doi.org/10.1182/blood-2018-99-116771

Published: 2018

Journal Articles

Suppression of FVIII Antibody Production By FVIII BAR T-Cell in Vitro in the Presence of Inhibitors

Kalpana Parvathaneni, PhD, Ai-Hong Zhang, PhD, David W. Scott, PhD

Blood (2018) 132 (Supplement 1): 3789.

https://doi.org/10.1182/blood-2018-99-115278

Published: 2018

Journal Articles

Fluid-Phase Immune Complexes Can Assemble and Activate Platelets in Heparin-Induced Thrombocytopenia

Angela Huynh, BSc, Donald M. Arnold, MD MSc, FRCPC, James W. Smith, Taylor D. Elliott, BSc, Hina Bhakta, John G. Kelton, MD, Ishac Nazy, PhD

Blood (2018) 132 (Supplement 1): 3746.

https://doi.org/10.1182/blood-2018-99-115037

Published: 2018

Journal Articles

Rituximab-Induced Acute Thrombocytopenia in a Patient with Relapsed Follicular Lymphoma

Jiang Yujie, MD, Na Wang, MD, Dai Yuan, MD, Huiting Qu, MD, Lili Feng, MD PhD, Juan Fan, MD, Xin Wang, MD PhD

Blood (2018) 132 (Supplement 1): 5343.

https://doi.org/10.1182/blood-2018-99-117608

Published: 2018

Journal Articles

CD38-Deficient, CD16-Engineered NK Cells Exhibit Enhanced Antibody-Dependent Cellular Cytotoxicity without NK Cell Fratricide to Augment Anti-Myeloma Immunity in Combination with Daratumumab

Karrune Woan, MD PhD, Ryan Bjordahl, PhD, Frank Cichocki, PhD, Svetlana Gaidarova, MS, Cameron Pride, BS, Dan S Kaufman, MD PhD, Karl-Johan Malmberg, MD PhD, Sarah Cooley, MD, Bahram Valamehr, PhD, Jeffrey S. Miller, MD

Blood (2018) 132 (Supplement 1): 3224.

https://doi.org/10.1182/blood-2018-99-116459

Published: 2018

Journal Articles

Preliminary Clinical Results of a Phase 1 Study Evaluating the Safety and Anti-Tumor Activity of ACTR707 in Combination with Rituximab in Subjects with Relapsed or Refractory CD20+ B-Cell Lymphoma

Ian W. Flinn, MD PhD, Jonathon B. Cohen, MD MS, Luke P. Akard, MD, Samantha Jaglowski, MD MPH, Michael Vasconcelles, MD, Ann Ranger, PhD, Patricia Harris, MPH, Francis Payumo, BSc, MSc, Greg Motz, PhD, Veronika Bachanova, MD PhD

Blood (2018) 132 (Supplement 1): 2966.

https://doi.org/10.1182/blood-2018-99-111622

Published: 2018

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

FcRn augments induction of tissue factor activity by IgG-containing immune complexes

Pluripotent stem cell–derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity

Ibrutinib Therapy Downregulates Toso, the Fcr for IgM, Expression in CLL Patients

T-Cell Mediated Cytopenias in Patients with Myelodysplastic Syndromes Respond to Intravenous Immunoglobulin

Phase I/II, Open-Label, Adaptive Study of Oral Bruton Tyrosine Kinase Inhibitor PRN1008 in Patients with Relapsed/Refractory Primary or Secondary Immune Thrombocytopenia

Impacts of a Proliferation-Inducing Ligand on Current Therapeutic Monoclonal Antibody-Induced Cytotoxicity Against Human Multiple Myeloma Cells

Understanding How Fc-Modification Transforms a Pathogenic Heparin-Induced Thrombocytopenia (HIT)-like Monoclonal Antibody into a Novel Treatment for Sepsis

Phase 2 Study of Efgartigimod, a Novel FcRn Antagonist, in Adult Patients with Primary Immune Thrombocytopenia

Rozanolixizumab, an Anti-FcRn Antibody: Final Results from a Phase II, Multiple-Dose Study in Patients with Primary Immune Thrombocytopenia

Pathogenic Antibodies in Heparin-Induced Thrombocytopenia Specifically Target an Immunodominant Region on Platelet Factor 4

Preclinical Characterization of an ANTI-CD38/CD3 T CELL-Redirecting Bispecific Antibody

Immune-Tumor Interactions in Resistance to Cancer Immunotherapy

Engineering High Affinity and Cleavage Resistant CD16 to Augment ADCC of Placental Hematopoietic Stem Cells-Derived Natural Killer Cells

Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia

Pre-Clinical Efficacy of CD123-Targeting Antibody-Drug Conjugate IMGN632 in Blastic Plasmacytoid Dentritic Cell Neoplasm (BPDCN) Models

Suppression of FVIII Antibody Production By FVIII BAR T-Cell in Vitro in the Presence of Inhibitors

Fluid-Phase Immune Complexes Can Assemble and Activate Platelets in Heparin-Induced Thrombocytopenia

Rituximab-Induced Acute Thrombocytopenia in a Patient with Relapsed Follicular Lymphoma

CD38-Deficient, CD16-Engineered NK Cells Exhibit Enhanced Antibody-Dependent Cellular Cytotoxicity without NK Cell Fratricide to Augment Anti-Myeloma Immunity in Combination with Daratumumab

Preliminary Clinical Results of a Phase 1 Study Evaluating the Safety and Anti-Tumor Activity of ACTR707 in Combination with Rituximab in Subjects with Relapsed or Refractory CD20+ B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only